Autoimmune Thrombotic Microangiopathy: Advances in Pathogenesis, Diagnosis, and Management

Abstract

Thrombotic microangiopathy, or the syndrome of thrombocytopenia and hemolysis with schistocytes on blood smears, has been a subject of uncertainty and intense controversy. The pathogenesis of thrombotic microangiopathy was unknown and no classification of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome was satisfactory. In recent years, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) deficiency and defective complement regulation have been identified as the two major causes of noninfectious thrombotic microangiopathy. It is now possible to classify thrombotic microangiopathy pathogenetically rather than clinically, and a distinction between diseases and clinical syndromes is emerging. This pathogenesis-based disease classification requires new diagnostic approaches and provides a framework for rational therapeutic designs. This review discusses the new concepts in the pathogenesis, diagnosis, and management of thrombotic microangiopathy, with particular emphasis on the autoimmune causes of ADAMTS-13 deficiency and defective complement regulation.

Keywords

thrombotic thrombocytopenic purpura - hemolytic uremic syndrome - thrombotic microangiopathy - autoimmunity - ADAMTS-13

• References

• 1 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Proc NY Pathol Soc 1924; 24: 21-24
• 2 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38 (5) 469-479
• 3 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
• 4 Levy GG, Nichols WC, Lian EC , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855) 488-494
• 5 Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr 1955; 85 (38–39) 905-909
• 6 Seger R, Joller P, Baerlocher K , et al. Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion. Helv Paediatr Acta 1980; 35 (4) 359-367
• 7 Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151 (5) 775-782
• 8 Kaplan BS, Chesney RW, Drummond KN. Hemolytic uremic syndrome in families. N Engl J Med 1975; 292 (21) 1090-1093
• 9 Richardson SE, Karmali MA, Becker LE, Smith CR. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988; 19 (9) 1102-1108
• 10 Taylor CM, Chua C, Howie AJ, Risdon RA ; British Association for Paediatric Nephrology. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol 2004; 19 (4) 419-425
• 11 Noris M, Caprioli J, Bresin E , et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5 (10) 1844-1859
• 12 Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 2010; 36 (6) 633-640
• 13 Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88 (8) 2939-2950
• 14 Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108 (6) 1903-1910
• 15 Schneider SW, Nuschele S, Wixforth A , et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 2007; 104 (19) 7899-7903
• 16 Zhou W, Inada M, Lee TP , et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85 (6) 780-788
• 17 Uemura M, Tatsumi K, Matsumoto M , et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106 (3) 922-924
• 18 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91 (1) 1-19
• 19 Tsai HM, Chandler WL, Sarode R , et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49 (5) 653-659
• 20 O'Brien JR, Tsai HM, Etherington MD. Defective von willebrand factor activity detected by the filterometer in three clinical conditions. Platelets 2000; 11 (7) 388-394
• 21 Vincentelli A, Susen S, Le Tourneau T , et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349 (4) 343-349
• 22 Yoshida K, Tobe S, Kawata M. Acquired von Willebrand disease type IIA in patients with aortic valve stenosis. Ann Thorac Surg 2006; 81 (3) 1114-1116
• 23 Uriel N, Pak SW, Jorde UP , et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56 (15) 1207-1213
• 24 Malehsa D, Meyer AL, Bara C, Strüber M. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Eur J Cardiothorac Surg 2009; 35 (6) 1091-1093
• 25 Geisen U, Heilmann C, Beyersdorf F , et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33 (4) 679-684
• 26 Sagripanti A, Carpi A. Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed Pharmacother 2000; 54 (2) 107-111
• 27 Boon CJ, van de Kar NC, Klevering BJ , et al. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol 2009; 46 (8–9) 1573-1594
• 28 Salmon JE, Heuser C, Triebwasser M , et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8 (3) e1001013
• 29 Coppo P, Bengoufa D, Veyradier A , et al; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83 (4) 233-244
• 30 Coppo P, Busson M, Veyradier A , et al; French Reference Centre For Thrombotic Microangiopathies. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010; 8 (4) 856-859
• 31 Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132 (10) 794-799
• 32 Sugio Y, Okamura T, Shimoda K , et al. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol 2001; 74 (3) 347-351
• 33 Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3 (7) 1432-1436
• 34 Camilleri RS, Cohen H, Mackie IJ , et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 6 (2) 331-338
• 35 Knecht ME, Mayr M, Ferrari S, Scheiflinger F, Trendelenburg M. A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13. Nephrol Dial Transplant 2010; 25 (5) 1720-1722
• 36 Thampi S, Salmi D, Imashuku S, Ducore J, Satake N. Thrombotic thrombocytopenic purpura in a child with systemic lupus erythematosus. J Pediatr Hematol Oncol 2011; 33 (3) 221-223
• 37 Pos W, Luken BM, Hovinga JA , et al. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7 (3) 421-428
• 38 Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7 (10) 1703-1710
• 39 Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106 (46) 19274-19279
• 40 Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118 (12) 3212-3221
• 41 Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?. J Biol Chem 2005; 280 (48) 39934-39941
• 42 Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93 (2) 267-274
• 43 Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010; 115 (8) 1640-1649
• 44 Klaus C, Plaimauer B, Studt JD , et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103 (12) 4514-4519
• 45 Luken BM, Kaijen PH, Turenhout EA , et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4 (11) 2355-2364
• 46 Zheng XL, Wu HM, Shang D , et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010; 95 (9) 1555-1562
• 47 Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284 (45) 30925-30932
• 48 Dayananda KM, Gogia S, Neelamegham S. Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Förster resonance energy transfer proteins that quantify ADAMTS13 activity. Anal Biochem 2011; 410 (2) 206-213
• 49 Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115 (8) 1500-1511 , quiz 1662
• 50 Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47 (7–8) 387-392
• 51 Zeigler ZR, Shadduck RK, Gryn JF , et al; North American TTP Group. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16 (1) 19-22
• 52 Rock G, Anderson D, Clark W , et al; Canadian Apheresis Group; Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129 (1) 79-86
• 53 Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000; 65 (3) 251-255
• 54 Dong L, Chandrasekaran V, Zhou W, Tsai HM. Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83 (10) 815-817
• 55 Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124 (6) 787-795
• 56 Cataland SR, Jin M, Ferketich AK , et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136 (1) 146-149
• 57 Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28 (3) 385-391
• 58 Scully M, McDonald V, Cavenagh J , et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118 (7) 1746-1753
• 59 Nosari A, Redaelli R, Caimi TM, Mostarda G, Morra E. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura. Am J Hematol 2009; 84 (5) 313-314
• 60 Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106 (3) 539-547
• 61 Ulrichts H, Silence K, Schoolmeester A , et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011; 118 (3) 757-765
• 62 Chen J, Reheman A, Gushiken FC , et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121 (2) 593-603
• 63 Józsi M, Strobel S, Dahse HM , et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110 (5) 1516-1518
• 64 Zipfel PF, Edey M, Heinen S , et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007; 3 (3) e41
• 65 Dragon-Durey MA, Blanc C, Marliot F , et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46 (7) 447-450
• 66 Bienaime F, Dragon-Durey MA, Regnier CH , et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010; 77 (4) 339-349
• 67 Dragon-Durey MA, Sethi SK, Bagga A , et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21 (12) 2180-2187
• 68 Moore I, Strain L, Pappworth I , et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115 (2) 379-387